Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A0B65S3
Wed, 30.11.2022
PAION AG
PAION AG announces change in Management Board
Chairman of the Executive Board Dr. James Phillips leaves the company effective 30 November 2022
Current Supervisory Board member Gregor Siebert will be appointed as a member and new Chairman of the Management Board until 30 November 2023
Aachen (Germany), 30 November 2022 - PAION AG (ISIN DE000A0B65S [ … ]
Wed, 30.11.2022
PAION AG
PAION AG announces change in Management Board
Chairman of the Executive Board Dr. James Phillips leaves the company effective 30 November 2022
Current Supervisory Board member Gregor Siebert will be appointed as a member and new Chairman of the Management Board until 30 November 2023
Aachen (Germany), 30 November 2022 - PAION AG (ISIN DE000A0B65S [ … ]
Wed, 16.11.2022
PAION AG
PAION AG enters partnership with Viatris and expands sales activities in Europe
Viatris, leveraging its Global Healthcare Gateway in partnership with Paion shall distribute the products Remimazolam, Eravacycline and Angiotensin II in a total of 7 European target markets
Focus remains on expansion of commercial sales in Europe
Aachen, Germany, 1 [ … ]
Wed, 16.11.2022
PAION AG
PAION AG enters partnership with Viatris and expands sales activities in Europe
Viatris, leveraging its Global Healthcare Gateway in partnership with Paion shall distribute the products Remimazolam, Eravacycline and Angiotensin II in a total of 7 European target markets
Focus remains on expansion of commercial sales in Europe
Aachen, Germany, 1 [ … ]
Wed, 16.11.2022
PAION AG
PAION AG reports financial results for the first nine months of 2022
Combined revenues of EUR 25.6 million
Cash and cash equivalents of EUR 10.4 million as of 30 September 2022
PAION raises guidance for 2022 and expects EBITDA in the corridor of EUR -1.5 million to EUR +0.5 million
Transformation into commercial specialty pharma company progres [ … ]
Wed, 16.11.2022
PAION AG
PAION AG reports financial results for the first nine months of 2022
Combined revenues of EUR 25.6 million
Cash and cash equivalents of EUR 10.4 million as of 30 September 2022
PAION raises guidance for 2022 and expects EBITDA in the corridor of EUR -1.5 million to EUR +0.5 million
Transformation into commercial specialty pharma company progres [ … ]
Mon, 14.11.2022
PAION AG
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
TTY Biopharm is planning to launch this new sedative in December 2022
Approximately 1.3 million invasive medical procedures take place annually in Taiwan, of which ~50-80% use moderate sedation
PAION already has selected partnerships to lice [ … ]
Mon, 14.11.2022
PAION AG
PAION AG’S PARTNER TTY BIOPHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM IN PROCEDURAL SEDATION IN TAIWAN
TTY Biopharm is planning to launch this new sedative in December 2022
Approximately 1.3 million invasive medical procedures take place annually in Taiwan, of which ~50-80% use moderate sedation
PAION already has selected partnerships to lice [ … ]
Wed, 31.08.2022
PAION AG
PAION AG reports financial results for the first half-year 2022
Transformation into commercial specialty pharma company continues
Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million
Expansion of partner networks through licensing [ … ]
Wed, 31.08.2022
PAION AG
PAION AG reports financial results for the first half-year 2022
Transformation into commercial specialty pharma company continues
Financial position strengthened to support commercial activities in Europe by sale of Chinese remimazolam patents and future royalties to Humanwell for EUR 20.5 million
Expansion of partner networks through licensing [ … ]